-
1.再颁专利Cyclic peptides, method for preparing and use as angiogenesis inhibitors or activators 有权循环肽，制备和用作血管发生抑制剂或激活剂的方法公开(公告)号：USRE44022E1
公开(公告)日：2013-02-19
申请号：US12418101
申请日：2001-10-02
申请人： Andreas Bikfalvi , Juliette Boulard , Antonin Boulard , Liliane Dequaire , Romane Boulard , Sara Boulard , Julie Deleris , Christiane Deleris , Marie Deleris
发明人： Natacha Betz , Andreas Bikfalvi , Gerard Deleris
摘要： The invention relates to cyclopeptides, the method of their preparation and their utilization as inhibitors or activators of angiogenesis.These cyclopeptides comprise contain the following peptide sequence: -Arg-Ile-Lys-Pro-His-Gln-Gly- (SEQ ID NO: 1). They can be used in systems for inhibition of angiogenesis that comprises include a support (1), to which the cyclopeptide is affixed by means of coupled via an organic spacer arm (3) that may be provided with a moiety (4) capable of being spliced cleaved by an enzyme system.
摘要翻译： 本发明涉及环肽，其制备方法及其作为血管生成抑制剂或活化剂的用途。 这些环肽包含以下肽序列：-Arg-Ile-Lys-Pro-His-Gln-Gly-（SEQ ID NO：1）。 它们可以用于抑制血管生成的系统中，其包括载体（1），通过有机间隔臂（3）与环化合物连接，所述支持物可以被提供有能够被 被酶切割的剪接。
-
2.发明申请POLYPEPTIDES DERIVED FROM THE HEMOPEXIN-LIKE DOMAIN OF METALLOPROTEINASE MMP-2 审中-公开衍生自金属蛋白酶MMP-2的HEMOPEXIN-like域的多肽公开(公告)号：US20100150872A1
公开(公告)日：2010-06-17
申请号：US12302690
申请日：2007-05-30
申请人： Andreas Bikfalvi , Carlo Sala , Lorenzo Bello
发明人： Andreas Bikfalvi , Carlo Sala , Lorenzo Bello
IPC分类号： A61K38/46 , C12N9/50 , C12N9/96 , C12N15/57 , C12N15/63 , C12N5/00 , A61K31/7052 , A61K35/12 , A61P35/00 , A61P19/02 , A61P3/10 , A61P17/06 , A61P17/00 , A61P29/00
CPC分类号： C12N9/6491
摘要： The present invention relates to anti-angiogenic polypeptides derived from the non catalytic C-terminal hemopexin-like domain of the metalloproteinase MMP-2. The invention also provides pharmaceutical compositions comprising said anti-angiogenic polypeptides and methods for using said polypeptide for treating angiogenic diseases, and in particular for treating cancer.
摘要翻译： 本发明涉及源自金属蛋白酶MMP-2的非催化性C-末端血凝素样结构域的抗血管生成多肽。 本发明还提供包含所述抗血管生成多肽的药物组合物和使用所述多肽治疗血管生成疾病，特别是用于治疗癌症的方法。
-
3.发明授权Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (PF4V1) 失效针对血小板因子-4变体1（PF4V1）的中和抗体及其片段公开(公告)号：US08481033B2
公开(公告)日：2013-07-09
申请号：US13122468
申请日：2009-10-07
IPC分类号： A61K39/00
CPC分类号： C07K16/24 , A61K49/0032 , A61K49/0058 , C07K2317/74 , C07K2317/76 , C07K2319/23
摘要： The present invention relates to neutralizing antibodies and fragments thereof directed against Platelet Factor-4 variant 1 (PF4v1) and their use for treating pathologies that require induction of angiogenesis or diseases associated with pathological angiogenesis.
摘要翻译： 本发明涉及针对血小板因子-4变体1（PF4v1）的中和抗体及其片段及其用于治疗需要诱导血管发生或与病理血管发生相关的疾病的病理学的用途。
-
公开(公告)号：US20110318370A1
公开(公告)日：2011-12-29
申请号：US13131084
申请日：2009-11-25
IPC分类号： A61K39/395 , A61P35/04 , A61P35/00 , C12Q1/68 , G01N33/566
CPC分类号： C12Q1/6886 , C12Q2600/112 , G01N33/507 , G01N2333/521
摘要： The invention relates to the use of CXCL4L1 as a biomarker of pancreatic cancer in a patient. More particularly, the invention relates to a method for detecting a pancreatic cancer and/or pancreatic metastasis in a patient, said method comprising determining the expression level of the CXCL4L1 gene in a biological sample obtained from said patient.
摘要翻译： 本发明涉及CXCL4L1作为患者胰腺癌生物标志物的用途。 更具体地，本发明涉及一种用于检测患者胰腺癌和/或胰腺转移的方法，所述方法包括测定从所述患者获得的生物样品中CXCL4L1基因的表达水平。
-
5.发明授权Cyclic peptides, method for preparing and use as angiogenesis inhibitors or activator 有权循环肽，制备和用作血管生成抑制剂或活化剂的方法公开(公告)号：US07199100B2
公开(公告)日：2007-04-03
申请号：US10381734
申请日：2001-10-02
申请人： Natacha Betz , Andreas Bikfalvi , Gerard Deleris
发明人： Natacha Betz , Andreas Bikfalvi , Gerard Deleris
摘要： The invention relates to cyclopeptides, the method of their preparation and their utilization as inhibitors or activators of angiogenesis.These cyclopeptides comprise the following peptide sequence: -Arg-Ile-Lys-Pro-His-Gln-Gly- They can be used in systems for inhibition of angiogenesis that comprises a support (1), to which the cyclopeptide is affixed by means of an organic spacer arm (3) that may be provided with a moiety (4) capable of being spliced by an enzyme system.
摘要翻译： 本发明涉及环肽，其制备方法及其作为血管生成抑制剂或活化剂的用途。
-
6.发明授权公开(公告)号：US08940702B2
公开(公告)日：2015-01-27
申请号：US13386696
申请日：2010-07-26
CPC分类号： C07K14/522 , A61K38/00
摘要： The present invention pertains to PF4 muteins which comprise a substitution at position 67, e.g. a L67H substitution, compared to the sequence of the wild-type PF4 protein. Such PF4 muteins exhibit an increased anti-angiogenie activity and a reduced affinity for proteoglycans compared to the wild-type PF4 protein.
摘要翻译： 本发明涉及PF4突变蛋白，其包含在位置67处的取代，例如 与野生型PF4蛋白的序列相比，L67H替代。 与野生型PF4蛋白相比，这种PF4突变蛋白表现出增加的抗血管生成活性和降低对蛋白聚糖的亲和力。
-
7.发明申请公开(公告)号：US20120157384A1
公开(公告)日：2012-06-21
申请号：US13386696
申请日：2010-07-26
IPC分类号： A61K38/19 , C07K7/06 , C12N15/19 , C12N1/21 , C12N1/19 , C12N1/15 , C12N5/10 , C12P21/02 , A61P35/00 , A61P29/00 , A61P9/00 , A61P31/00 , A61P17/00 , A61P11/00 , A61P1/00 , A61P15/00 , A61P19/08 , A61P19/02 , A61P3/10 , A61P3/04 , C07K14/52
CPC分类号： C07K14/522 , A61K38/00
摘要： The present invention pertains to PF4 muteins which comprise a substitution at position 67, e.g. a L67H substitution, compared to the sequence of the wild-type PF4 protein. Such PF4 muteins exhibit an increased anti-angiogenie activity and a reduced affinity for proteoglycans compared to the wild-type PF4 protein.
摘要翻译： 本发明涉及PF4突变蛋白，其包含在位置67处的取代，例如 与野生型PF4蛋白的序列相比，L67H替代。 与野生型PF4蛋白相比，这种PF4突变蛋白表现出增加的抗血管生成活性和降低对蛋白聚糖的亲和力。
-
8.发明申请Neutralizing Antibodies and Fragments Thereof Directed Against Platelet Factor-4 Variant 1 (PF4V1) 失效针对血小板因子-4变体1（PF4V1）的中和抗体及其片段公开(公告)号：US20110250210A1
公开(公告)日：2011-10-13
申请号：US13122468
申请日：2009-10-07
IPC分类号： A61K39/395 , C07H21/00 , C12N15/63 , C12N5/10 , C12N1/00 , C12P21/00 , G01N33/566 , A61P35/00 , A61P27/02 , A61P7/02 , A61P7/00 , A61P9/10 , A61P9/12 , A61P3/10 , A61P9/00 , A61P29/00 , C07K16/24
CPC分类号： C07K16/24 , A61K49/0032 , A61K49/0058 , C07K2317/74 , C07K2317/76 , C07K2319/23
摘要： The present invention relates to neutralizing antibodies and fragments thereof directed against Platelet Factor-4 variant 1 (PF4v1) and their use for treating pathologies that require induction of angiogenesis or diseases associated with pathological angiogenesis.
摘要翻译： 本发明涉及针对血小板因子-4变体1（PF4v1）的中和抗体及其片段及其用于治疗需要诱导血管发生或与病理血管发生相关的疾病的病理学的用途。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.014 秒)
